Top 5 Drug Type | Count |
---|---|
Small molecule drug | 12 |
Biosimilar | 2 |
Recombinant polypeptide | 1 |
Monoclonal antibody | 1 |
Bispecific T-cell Engager (BiTE) | 1 |
Mechanism GR agonists [+3] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date01 May 2020 |
Target |
Mechanism GR agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. AU |
First Approval Date11 Dec 2019 |
Target |
Mechanism PRKAB1 activators [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. IN |
First Approval Date18 Aug 2019 |
Start Date10 Jun 2024 |
Sponsor / Collaborator |
Start Date30 Apr 2024 |
Sponsor / Collaborator Ichnos Sciences, Inc.Startup [+1] |
Start Date29 Dec 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Metformin/Remogliflozin etabonate ( PRKAB1 x SGLT2 ) | Diabetes Mellitus, Type 2 More | Approved |
Metformin Hydrochloride/Rosiglitazone Maleate ( PPARγ x PRKAB1 ) | Diabetes Mellitus, Type 2 More | Approved |
Olanzapine ( 5-HT2A receptor x 5-HT2C receptor x 5-HT3 receptor x D2 receptor ) | Bipolar Disorder More | Approved |
Formoterol Fumarate/Glycopyrrolate ( mAChRs x β2-adrenergic receptor ) | Pulmonary Disease, Chronic Obstructive More | Approved |
Liraglutide biosimilar(Glenmark) ( GLP-1R ) | Diabetes Mellitus, Type 2 More | Approved |